The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the treatment of catamenial epilepsy. We propose that since the catamenial seizures are associated with the reduction in levels of GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent Phenobarbital will reduce the incidence of catamenial seizures.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Phenobarbital will be given based on weight range
Placebo group
University of Toledo, Health Science Campus
Toledo, Ohio, United States
Patient Health Questionnaire (PHQ-9)
Time frame: Screening, 3 month and final visit
Depression Epworth Sleepiness Scale (ESS)
Time frame: Screening, 3 month and final visit
Quality of Life in Epilepsy (QOLIE-10)
Time frame: Screening, 3 month and Final Visit
Addenbrooke's Cognitive Examination (ACE)
Time frame: Screening, 3 month and Final Visit
Determine tolerance of medication using the depression, cognitive and sleepiness screening tools listed above
Time frame: Screening, 3 months, final visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.